EATG » ViiV Healthcare announces CHMP Positive Opinion for Dovato®

ViiV Healthcare announces CHMP Positive Opinion for Dovato®

ViiV Healthcare announces CHMP Positive Opinion for Dovato® (dolutegravir/lamivudine) as a once-daily, single-pill, two-drug regimen for the treatment of HIV infection

— Recommendation based on landmark GEMINI 1 & 2 studies which demonstrated non-inferior efficacy of dolutegravir + lamivudine compared to a traditional dolutegravir-based, three-drug regimen, in HIV-1 infected, treatment-naïve adults

Read the press release here.


 

Source:
ViiV Healthcare
News categories: HIV treatment, EMA/FDA